Saisei Ventures

Saisei Ventures is a venture capital firm that builds biotechnology companies, connecting Japanese innovation with global expertise across early-stage biotechnology and life-science opportunities. The firm's technical scope spans cell therapies, gene therapies, regenerative medicine and advanced therapeutic platforms, with process development treated as a core component of company building rather than an afterthought.

The firm operates from offices in Cambridge, Massachusetts and Tokyo, Japan, positioning it between two of the more active biotechnology ecosystems. Its portfolio includes Craif, CureApp, Kenai Therapeutics, Notch Therapeutics and Tune Therapeutics. Notch Therapeutics and Tune Therapeutics sit in cell therapy and epigenetic editing respectively; Kenai Therapeutics is developing cell-based therapies for neurological disease; CureApp develops digital therapeutics; and Craif works on early cancer detection.

Saisei Ventures describes a hands-on, science-first approach, working alongside scientists, founders and industry experts. Beyond capital, the firm supplies entrepreneurial and operational guidance, process-development leadership, and introductions to global business partners and investors. The stated objective is to build globally competitive companies addressing serious diseases and improving patient outcomes.